Fundraising Fox
Atanis Biotech
Founded 2021 · 28 employees on LinkedIn · 1 known investors
Find your way into Atanis Biotech
Sign up to see every warm intro you have to Atanis Biotech
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Atanis Biotech team. We find them
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes you can't see from your own inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Atanis Biotech develops FAST-PASE®, a blood-based allergy diagnostic test that measures how a patient's blood activates mast cells in response to specific food and other allergens, avoiding skin pricks and food challenges. The test targets common food allergens (egg, milk, peanut, cashew) and Alpha-gal red meat allergy, and is currently in development for use by patients and healthcare providers.
Founders & leadership
Atanis Biotech was founded in 2021 by Prof. Dr. Alexander Eggel, Prof. Dr. Thomas Kaufmann, and Prof. Dr. Jean-Pierre Kinet.
Investors · 1
Related companies · 2
Companies working in the same space as Atanis Biotech.
Frequently asked questions
- What does Atanis Biotech do?
- Atanis Biotech develops FAST-PASE®, a blood-based allergy diagnostic test that measures how a patient's blood activates mast cells in response to specific food and other allergens, avoiding skin pricks and food challenges. The test targets common food allergens (egg, milk, peanut, cashew) and Alpha-gal red meat allergy, and is currently in development for use by patients and healthcare providers.
- Who founded Atanis Biotech?
- Atanis Biotech was founded by Prof. Dr. Alexander Eggel, Prof. Dr. Thomas Kaufmann, Prof. Dr. Jean-Pierre Kinet in 2021.
- Who are Atanis Biotech's investors?
- Atanis Biotech's investors include Allerfund Ventures, Llc.